Vincent, Laure http://orcid.org/0000-0001-5904-1286
Gras, Luuk
Ceballos, Patrice
Finke, Jürgen
Passweg, Jakob
Harel, Stéphanie http://orcid.org/0000-0002-9469-8336
Rosinol, Laura
Minnema, Monique http://orcid.org/0000-0002-3139-8379
Teipel, Raphael
van Doesum, Jaap http://orcid.org/0000-0003-0214-3219
Hänel, Mathias
Lenain, Pascal
Botella-Garcia, Carmen
Koenecke, Christian http://orcid.org/0000-0001-7025-1735
Ducastelle, Sophie
Sanz, Jaime http://orcid.org/0000-0001-6934-4619
Schroyens, Wilfried
Zuckerman, Tsila http://orcid.org/0000-0002-6204-977X
Monaco, Federico http://orcid.org/0000-0002-4630-753X
Koster, Linda
de Wreede, Liesbeth
Hayden, Patrick J. http://orcid.org/0000-0003-1374-4503
Schönland, Stefan http://orcid.org/0000-0002-4853-5579
Yakoub-Agha, Ibrahim http://orcid.org/0000-0003-4524-8782
Beksac, Meral http://orcid.org/0000-0003-1797-8657
Article History
Received: 25 August 2021
Revised: 5 December 2021
Accepted: 23 December 2021
First Online: 10 January 2022
Competing interests
: Laure Vincent: consultancy: Janssen Cilag. Monique Minemma: consultancy: Alnylam, Janssen Cilag and Gilead, speakers Bureau: BMS and hospitality from Celgene. Raphael Teipel: honoraria: Janssen. Mathias Hanel: consultancy/advisory boards: Celgene, Amgen, Novartis, Takeda, GSK, honoraria: Celgene, Novartis, Takeda. Tsila Zuckerman: advisory board or speaker’s bureau: AbbVie, Orgenesis Inc, BioSight Ltd, Cellect Biotechnology, Janssen, Novartis and Gilead Sciences. Stefan Schönland: honoraria: Janssen Cilag, Prothena, Takeda, Pfizer, research funding: Janssen Cilag, Sanofi, Prothena. Ibrahim Yakoub-Agha: honoraria: Celgene/BMS, Kite/Gilead, Janssen Cilag and Novartis. Meral Beksac: advisory board and speakers bureau: Amgen, Celgene, Janssen, Sanofi, Takeda, Oncopeptides. The remaining authors declare no competing interests.